Description:
This is a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or
venetoclax in subjects with AML or high-risk MDS.
For all subjects, TP53wt status must be characterized by, at a minimum, no mutations noted in
exons 5, 6, 7 and 8.
Two treatment arms will enroll subjects in parallel to characterize the safety, tolerability,
PK, PD and preliminary antitumor activity of HDM201+MBG453 (treatment arm 1) and
HDM201+venetoclax (treatment arm 2).
- In the treatment arm 1, subjects will receive HDM201 in combination with MBG453.
- In the treatment arm 2, subjects will receive HDM201 in combination with venetoclax.
Venetoclax dose will be gradually increased (ramp-up) over a period of 4 to 5 days to
achieve the daily target dose tested that will be subsequently continued.
Upon the completion of the escalation part, MTD(s) and/or RD(s) of HDM201 in combination with
MBG453 or venetoclax in AML and high-risk MDS subjects will be determined for each treatment
arm.
Title
- Brief Title: HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
- Official Title: A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Clinical Trial IDs
- ORG STUDY ID:
CHDM201H12101C
- SECONDARY ID:
2018-004001-62
- NCT ID:
NCT03940352
Conditions
- Acute Myeloid Leukemia (AML)
- High-risk Myelodysplastic Syndrome (MDS)
Interventions
Drug | Synonyms | Arms |
---|
HDM201 | | treatment arm1: HDM201+MBG453 |
MBG453 | | treatment arm1: HDM201+MBG453 |
Venetoclax | | treatment arm2: HDM201+venetoclax |
Purpose
This is a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or
venetoclax in subjects with AML or high-risk MDS.
For all subjects, TP53wt status must be characterized by, at a minimum, no mutations noted in
exons 5, 6, 7 and 8.
Two treatment arms will enroll subjects in parallel to characterize the safety, tolerability,
PK, PD and preliminary antitumor activity of HDM201+MBG453 (treatment arm 1) and
HDM201+venetoclax (treatment arm 2).
- In the treatment arm 1, subjects will receive HDM201 in combination with MBG453.
- In the treatment arm 2, subjects will receive HDM201 in combination with venetoclax.
Venetoclax dose will be gradually increased (ramp-up) over a period of 4 to 5 days to
achieve the daily target dose tested that will be subsequently continued.
Upon the completion of the escalation part, MTD(s) and/or RD(s) of HDM201 in combination with
MBG453 or venetoclax in AML and high-risk MDS subjects will be determined for each treatment
arm.
Trial Arms
Name | Type | Description | Interventions |
---|
treatment arm1: HDM201+MBG453 | Experimental | Phase Ib (escalation) | |
treatment arm2: HDM201+venetoclax | Experimental | Phase Ib (escalation) | |
Eligibility Criteria
Main Inclusion Criteria:
- Male or female patients ≥ 18 years of age at the date of ICF signature who present
with one of the following:
1. Relapsed/refractory AML following ≥1 prior therapies (but ≤3 prior therapies) who
have relapsed or exhibited refractory disease (primary failure) and are deemed by
the Investigator not to be candidates for standard therapy, including
re-induction with cytarabine or other established chemotherapy regimens for
patients with AML (patients who are suitable for standard re-induction
chemotherapy or hematopoietic stem cell transplantation and willing to receive it
are excluded)
2. First line AML patient unfit for standard induction chemotherapy (includes both
de novo and secondary AML), except in countries where approved therapies are
available. Patients who are suitable for hematopoietic stem cell transplantation
and willing to receive it are excluded.
3. High-risk MDS patient (high and very high-risk groups according to rIPSS) who
have failed hypomethylating agent therapy.
- ECOG performance status ≤ 1
- TP53wt tumor. At minimum exons 5, 6, 7 and 8 in the TP53 gene must be sequenced and
determined to contain no mutations. The TP53 status must be obtained from a
bone-marrow sample, collected no longer than 3 months before signing the main ICF.
- Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to
the institutional guidelines and be willing to undergo a bone marrow aspirate and/or
biopsy at screening, during and at the end of therapy on this study. Exceptions may be
considered after documented discussion with Novartis.
Main Exclusion Criteria:
Patients eligible for this study must not meet any of the following criteria:
- Prior combination treatment with compounds having the same mode of action:
- mdm2 or mdm4 inhibitors combined with TIM-3 inhibitors (for patients enrolled in
treatment arm1)
- mdm2 or mdm4 inhibitors combined with Bcl-2 inhibitor (for patients enrolled in
treatment arm2)
- History of severe hypersensitivity reactions to any ingredient of study drug(s) and
other monoclonal antibodies (mAbs) and/or their excipients.
- Patients with acute promyelocytic leukemia with PML-RARA.
- Allogeneic stem cell transplant (HSCT) within last 6 months and/or active GvHD
requiring systemic immunosuppressive therapy.
- GI disorders impacting absorption of oral HDM201 or venetoclax.
- Evidence of active bleeding or bleeding diathesis or major coagulopathy (including
familial).
- Patients with active, known or suspected autoimmune disease (treatment arm 1 only).
Other eligibility criteria apply.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety |
Time Frame: | at month 24 |
Safety Issue: | |
Description: | Month 24 is assumed to be study end |
Secondary Outcome Measures
Measure: | Overall Response Rate (ORR) |
Time Frame: | at month 24 |
Safety Issue: | |
Description: | Month 24 is assumed to be study end |
Measure: | Best Overall Response (BOR) |
Time Frame: | at month 24 |
Safety Issue: | |
Description: | Month 24 is assumed to be study end |
Measure: | Event Free Survival (EFS) for AML (Cheson 2003) or Progression Free Survival (PFS) for MDS (Cheson 2006) |
Time Frame: | at month 24 |
Safety Issue: | |
Description: | Month 24 is assumed to be study end |
Measure: | Relapse Free Survival (RFS) for AML (Cheson 2003) or Time To Response (TTR) for MDS (Cheson 2006) |
Time Frame: | at month 24 |
Safety Issue: | |
Description: | Month 24 is assumed to be study end |
Measure: | Duration Of Response (DOR) for AML (Cheson 2003) and MDS (Cheson 2006) |
Time Frame: | at month 24 |
Safety Issue: | |
Description: | Month 24 is assumed to be study end |
Measure: | Presence of anti-MBG453 antibodies (treatment arm 1 HD201+MBG453) |
Time Frame: | at Day 1, Day 29 and at month 24 |
Safety Issue: | |
Description: | |
Measure: | Concentration of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) |
Time Frame: | at Day 1, Day 2, Day 5, Day 6 and Day 29 |
Safety Issue: | |
Description: | |
Measure: | Concentration of MBG453 (treatment arm 1 HDM201+MBG453) |
Time Frame: | at Day 1, Day 2, Day 8, Day 11, Day 15, Day 29 and at month 24 |
Safety Issue: | |
Description: | |
Measure: | Concentration of venetoclax (treatment arm 2 HDM201+venetoclax) |
Time Frame: | at Day 1, Day 2, Day 3, Day 5, Day 6, Day 8, Day 9, Day 14, Day 15 and Day 29 |
Safety Issue: | |
Description: | |
Measure: | PK parameter (AUC) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) |
Time Frame: | at month 6 |
Safety Issue: | |
Description: | Cycle 6 |
Measure: | PK parameter (Cmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) |
Time Frame: | at month 6 |
Safety Issue: | |
Description: | Cycle 6 |
Measure: | PK parameter (Tmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) |
Time Frame: | at month 6 |
Safety Issue: | |
Description: | Cycle 6 |
Measure: | PK parameter (AUC) of MBG453 (treatment arm 1 HDM201+MBG453) |
Time Frame: | at month 6 |
Safety Issue: | |
Description: | Cycle 6 |
Measure: | PK parameter (Cmax) of MBG453 (treatment arm 1 HDM201+MBG453) |
Time Frame: | at month 6 |
Safety Issue: | |
Description: | Cycle 6 |
Measure: | PK parameter (Tmax) of MBG453 (treatment arm 1 HDM201+MBG453) |
Time Frame: | at month 6 |
Safety Issue: | |
Description: | Cycle 6 |
Measure: | PK parameter (AUC) of venetoclax (treatment arm 2 HDM201+venetoclax) |
Time Frame: | at month 6 |
Safety Issue: | |
Description: | Cycle 6 |
Measure: | PK parameter (Cmax) of venetoclax (treatment arm 2 HDM201+venetoclax) |
Time Frame: | at month 6 |
Safety Issue: | |
Description: | Cycle 6 |
Measure: | PK parameter (Tmax) of venetoclax (treatment arm 2 HDM201+venetoclax) |
Time Frame: | at month 6 |
Safety Issue: | |
Description: | Cycle 6 |
Measure: | Changes from baseline in GDF-15 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax) |
Time Frame: | at Day 1 and Day 2 |
Safety Issue: | |
Description: | |
Measure: | Changes from baseline in soluble TIM-3 (Treatment arm 1 HDM201+MBG453) |
Time Frame: | at month 6 |
Safety Issue: | |
Description: | Cycle 6 |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Novartis Pharmaceuticals |
Trial Keywords
- Phase Ib
- BHLRM
- AML
- MDS
- HDM201
- TP53
- MBG453
- TIM-3
- venetoclax
- Bcl-2
Last Updated
July 27, 2021